BMO Capital Sees Limited Near-Term Impact on Biogen (BIIB) from Interference Decision
Get Alerts BIIB Hot Sheet
Rating Summary:
29 Buy, 13 Hold, 0 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
BMO Capital analyst Jim Birchenough reiterated an Outperform rating and $511 price target on Biogen (NASDAQ: BIIB), saying Forward Pharma (FWP) Interference Decision was expected and they see limited near-term impact.
Birchenough commented, "We reiterate our Outperform rating on shares of BIIB following the USPTO update and interference decision. While a senior party claim could provide significant advantage to Forward Pharma, we believe that this decision was expected in BIIB shares and unlikely to impact valuation in the near term. Ultimately with the court process likely to extend beyond 2015 and with Forward Pharma yet to initiate phase 3 in MS as of yet we see competitive risk as far off, with potential settlement for TECFIDERA royalty as one potential option to lift the overhang. Fundamentally at the point where Forward Pharma was a legitimate commercial risk, we expect BIIB to have larger, longer lived opportunities to offset risk, in particular aducanumab for Alzheimer's"
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $423.36 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 4D Molecular Therapeutics (FDMT) PT Lowered to $63 at BMO Capital, 'uncertainty remains a lingering overhang until the PhIII readout'
- Cantor Fitzgerald Downgrades Caledonia Mining Corporation (CMCL) to Hold
- AO World Plc. (AO/:LN) PT Raised to GBP1.25 at Jefferies
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!